New York (December 13th, 2012) - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) 5.01 +0.58 (13.09%). Acadia Pharmaceuticals has capitalized on a rejuvenated stock price with an $86.4 million financing deal that will pay for a Phase III confirmatory study of its hot candidate pimavanserin in Parkinson's disease. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. Acadia's increased financial firepower gives the company resources to continue its journey with pimavanserin, an oral 5-HT2A receptor inverse agonist.
Get all the tips and hints traders need when trading ACAD by getting the free full report here: http://www.wallstreetscoop.net/market-scan/?symbol=ACAD
BG Medicine, Inc. (NASDAQ: BGMD) 3.19, -0.19 (-5.62%). BG Medicine, Inc. (Nasdaq:BGMD) announced that it has obtained a CE Mark enabling the commercial sale of the CardioSCORE™ test in the EU and other countries that recognize the CE Mark. The CardioSCORE test is the company's patented diagnostic blood test designed to dramatically improve risk prediction of major cardiovascular events beyond traditional risk factor assessments, such as the Framingham Risk Score and European SCORE. BG Medicine, Inc., is a United States-based company, which provides drug research and development services. The Company focused on the discovery, development, and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs.
WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.
WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetScoop.net
Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.
Wall Street Scoop
SOURCE Investor Alley, Inc.